Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Physical exercise can play an important role both in primary and secondary cardiovascular disease prevention by virtue of its multisystem effects. These beneficial adaptations at the whole-body level include improvements in mitochondrial health, vascular function, and autonomic balance, together with attenuation of inflammation and the release of 'exerkines' with pleiotropic effects. Thus, several research groups have attempted to develop so-called 'exercise pills' or 'exercise mimetics': that is, substances that are theoretically capable of reproducing some of the cardiometabolic benefits associated with regular exercise. In this review we summarize pharmacological and phytochemical agents which, when used alone or in combination with exercise, may improve cardiometabolic health. We also discuss the current gaps and future steps needed to translate these findings into therapeutic applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tem.2025.07.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From Gut Inflammation to Cardiovascular Conflagration: Mapping IBD's Cardiometabolic Risks.
Curr Atheroscler Rep
September 2025
Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Health, Houston Methodist Hospital, Houston, TX, USA.
Purpose Of Review: This review aims to characterize the known cardiovascular (CV) manifestations associated with inflammatory bowel disease (IBD) and the underlying mechanisms driving these associations.
Recent Findings: Gut dysbiosis, a hallmark of patients with IBD, can result in both local and systemic inflammation, thereby potentially increasing the risk of cardiovascular disease (CVD) in the IBD population. Micronutrient deficiencies, anemia, and sarcopenia independently increase the risk of CVD and are frequent comorbidities of patients with IBD.
Associations of sleep duration and quality with risk of incident obesity, diabetes, and metabolic syndrome: Results from the Midlife in the United States study.
Chronobiol Int
September 2025
Consultant, Wayzek Science, St Paul, Minnesota, USA.
Understanding how sleep affects the risk of incident chronic conditions in midlife may reinforce the importance of a healthy sleep pattern for healthy aging and cardiometabolic health. The objective of the study was to examine associations of sleep duration and quality with incident obesity, diabetes and metabolic syndrome in mid-aged adults. Participants without obesity ( = 381), diabetes ( = 509), or metabolic syndrome ( = 487) from the Biomarker Projects in Midlife in the United States study were examined separately for baseline sleep duration and quality and their associations with incident obesity, diabetes, or metabolic syndrome after an average follow-up of 12 years.
View Article and Find Full Text PDFPlasma Proteomic High-Performance Biomarkers for Early Diagnosis of Colorectal Cancer.
J Proteome Res
September 2025
Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu 610041, China.
Colorectal cancer (CRC) is a major global health challenge due to its high incidence, mortality, and low rate of early detection. Early diagnosis, targeting precancerous lesions (advanced adenomas) and early stage CRC (Tis and T1), is critical for improving patient survival. Given the limitations of current detection methods for advanced adenomas, developing high-performance early diagnostic strategies is essential for effective prevention.
View Article and Find Full Text PDFComposite endpoints in health technology assessment: part 2 - expanding the evidence base with a framework for best modeling practice.
J Comp Eff Res
September 2025
British Heart Foundation, University of Glasgow, Glasgow, UK.
The first paper of this two-part series critically examined the role of composite endpoints in health technology assessments (HTAs) and outlined strategies for determining whether to employ the composite estimate of treatment effect or disaggregate into the component endpoints of the composite and apply separate treatment effects within a modeling framework. In this second paper, we expand the discussion beyond a pivotal trial and consider the way in which additional evidence from the same indication for different drugs in the same class, or the same drug for different indications, could be employed within HTAs. We offer a continuation of the case study of dapagliflozin for the treatment of heart failure with preserved or mildly reduced ejection fraction, where the evidence base was expanded to consider empagliflozin for the same indication, as well as both dapagliflozin and empagliflozin for heart failure with reduced ejection fraction.
View Article and Find Full Text PDFComposite endpoints in health technology assessment: Part 1 - an illustration of best modeling practice.
J Comp Eff Res
September 2025
British Heart Foundation, University of Glasgow, Glasgow, UK.
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory approval. However, employing composite endpoints introduces complexities into health technology assessments (HTAs), particularly in economic modeling, due to the varying clinical significance and cost implications of the components. In this paper, we explore best modeling practice for HTAs that are based on clinical trials that employ composite endpoints.
View Article and Find Full Text PDF